Targeted Treatment Options for Patients With AML and FLT3 or IDH1/2 Mutations

CCO Oncology Podcast - Un podcast de Clinical Care Options

In this podcast episode, Sarah M. Tinsley, PhD, APRN, AOCN, discusses using targeted therapies in patients with FLT3- or IDH1/2-mutated AML.